Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472849 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT00472849: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00472849 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00472849, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of fludarabine and cytarabine that can be given in combination with oxaliplatin and rituximab in the treatment of chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, or Richter's transformation. Once the highest tolerable dose for this drug combination is found, the next goal of the study will be to find out if this combination therapy is effective in shrinking or slowing the growth of these diseases.
Interventions
- DRUG Fludarabine
- DRUG Oxaliplatin
- DRUG Rituximab
- DRUG Cytarabine
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472849
The ClinicalTrials.gov registry entry for NCT00472849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00472849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472849 about?
NCT00472849 is a clinical study titled "Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias". The goal of this clinical research study is to find the highest tolerable dose of fludarabine and cytarabine that can be given in combination with oxaliplatin and rituximab in the treatment of chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, or Richter's transformation. Once the highest ...
What is the current status of trial NCT00472849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2007-05. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00472849?
The interventions under investigation include: Fludarabine (DRUG), Oxaliplatin (DRUG), Rituximab (DRUG), Cytarabine (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT00472849?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.